Sunitinib malate in the treatment of urothelial cancer

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 115-124

  Pons, Francesc ^a   Bellmunt, Joaquim ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Bladder cancer; Sunitinib; Urothelial carcinoma

Indexed keywords

AXITINIB; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; DOVITINIB; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLT3 LIGAND; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; IMATINIB; INTERLEUKIN 8; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; MITOMYCIN; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN RET; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TIVOZANIB; VASCULOTROPIN; VINBLASTINE;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CREATININE CLEARANCE; CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE CHEMOTHERAPY; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SARCOMA; SIGNAL TRANSDUCTION; THERAPY EFFECT; THROMBOCYTOPENIA; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRROLES; UROGENITAL NEOPLASMS;

EID: 84889856078     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.853740     Document Type: Article

References (82)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374(9685):239-49
3. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485-90
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859-66 (Pubitemid 37025405)
5. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171-7
6. Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48(2):189-99, discussion 199-201
7. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77
8. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10(7):1066-73
9. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050-5 (Pubitemid 20200193)
10. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602-8 (Pubitemid 46224062)
11. NCCN. Guidelines. Clinical Practice Guidelines in Oncology. Bladder Cancer. V.1. 2013. Available from: http://www.nccn.org/professionals/physician- gls/PDF/bladder.pdf 2011 [Last accessed on May 2013]
12. Bellmunt J, Orsola A, Wiegel T, et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi45-9
13. Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012;118(1):72-81
14. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107(3):506-13 (Pubitemid 44107210)
15. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29(17):2432-8
16. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191-9
17. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454-61
18. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008;113(6):1284-93
19. Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol 2007;34(2):154-64 (Pubitemid 46436116)
20. Pinto A, Redondo A, Zamora P, et al. Angiogenesis as a therapeutic target in urothelial carcinoma. Anticancer Drugs 2010;21(10):890-6
21. Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6(12):4866-73 (Pubitemid 32110431)
22. Reiher F, Ozer O, Pins M, et al. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002;167(3):1469-74 (Pubitemid 34132134)
23. Goddard JC, Sutton CD, Furness PN, et al. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003;9(7):2583-6 (Pubitemid 36842100)
24. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154(1):69-71
25. Canoglu A, Gogus C, Beduk Y, et al. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36(3):401-5
26. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87(21):1603-12
27. Sagol O, Yorukoglu K, Sis B, et al. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder Urology 2001;57(5):895-9 (Pubitemid 32405308)
28. Dinney CP, Babkowski RC, Antelo M, et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 1998;160(4):1285-90 (Pubitemid 29480499)
29. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36(2):127-37
30. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29(6 Suppl 16):3-9
31. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60(15):4251-5 (Pubitemid 30636613)
32. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60(9):2497-503 (Pubitemid 30262444)
33. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29(6 Suppl 16):10-14
34. Wu W, Shu X, Hovsepyan H, et al.Freceptor expression and signaling in human bladder tumors. Oncogene 2003;22(22):3361-70 (Pubitemid 36713733)
35. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009;11(3):244-9
36. Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22(1):1-6
37. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001;8(1):9-15
38. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57(23):5281-5 (Pubitemid 27516364)
39. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001;166(4):1275-9 (Pubitemid 32862155)
40. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6(12):4874-84 (Pubitemid 32110432)
41. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95 (Pubitemid 36554699)
42. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004;18(2):338-40
43. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79(6):1190-4 (Pubitemid 27118614)
44. Li N, Kanda K, Fukumori T, et al. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer. Urol Oncol 2000;6(1):10-15
45. Li S, Nomata K, Sawase K, et al. Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. Int J Urol 2001;8(9):478-82 (Pubitemid 32953818)
46. Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005;95(3):425-31 (Pubitemid 40283138)
47. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
48. Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 2013;22(1):103-15
49. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26(4):626-32 (Pubitemid 351264358)
50. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127-34 (Pubitemid 39296599)
51. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329- 38 (Pubitemid 44528723)
52. Shams TM, Metawea M, Salim EI. c-KIT positive schistosomal urinary bladder carcinoma are frequent but lack KIT gene mutations. Asian Pac J Cancer Prev 2013;14(1):15-20
53. Pan CX, Yang XJ, Lopez-Beltran A, et al. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 2005;18(3):320-3 (Pubitemid 40395348)
54. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27(4):391-9
55. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35 (Pubitemid 46630490)
56. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61(3):515-24 (Pubitemid 350275988)
57. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30(12):1371-7
58. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
59. Chan ES, Patel AR, Hansel DE, et al. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology 2012;80(3):736 e1-5
60. Takeuchi A, Eto M, Shiota M, et al. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol 2012;40(5):1691-6
61. Yoon CY, Lee JS, Kim BS, et al. Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol 2011;52(1):55-63
62. Wu CL, Ping SY, Yu CP, Yu DS. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci 2012;28(4):194-203
63. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28(8):1373-9
64. Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, et al. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol 2011;60(2):344-9
65. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22(12):2646-53
66. Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007;5(7):460-3 (Pubitemid 351219702)
67. Grivas P, Nanus DM, Stadler WM. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012;30(Suppl 5):abstract 265
68. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012;11(2):175-81
69. Reck M, Frickhofen N, Cedres S, et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010;70(2):180-7
70. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115(18):4090-5
71. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012;13(8):810-16
72. Pili R, Qin R, Flynn PJ, Picus M. MC0553: a phase II safety and efficacy study with VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol 2011;29(Suppl 7):abstract 259
73. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-9 (Pubitemid 46797957)
74. Nathan PD, Vinayan A, Stott D, et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010;9(1):15-19
75. Smith AD, Shah SN, Rini BI, et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-8
76. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29(12):1525-30
77. Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013;31(6):724-30
78. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the university of texas M.D. Anderson cancer center. J Clin Oncol 2012;30(Suppl):abstract 4523
79. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81 (Pubitemid 29470648)
80. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28(11):1850-5
81. Pond GR, Agarwal N, Bellmunt J. Impact of baseline prognostic factors on progression-free survival at 6 onths (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol 2013;31(Suppl 6):abstract 301
82. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer-an update. Urol Oncol 2007;25(5):433-8 (Pubitemid 47362765)